±â»ç (Àüü 301°Ç) |
|
|
|
[Case Review] ½É½Ç ±â¿Ü ¼öÃà ȯÀÚ¿¡¼ Rytmonorm SR ó¹æ Áõ·Ê
Áõ·Ê76¼¼ ³²ÀÚ È¯ÀÚ°¡ ÀÏÂ÷ ÀÇ·á ±â°ü¿¡¼ ¾È°ú ¼ö¼ú Àü ½ÃÇàÇÑ ½ÉÀüµµ»ó ºó¹øÇÑ ½É½Ç ±â¿Ü ¼öÃàÀÌ °üÂûµÇ¾î ¿Ü·¡¸¦ ¹æ¹®ÇÏ¿´´Ù. ³»¿ø½Ã ÁöÂüÇÑ ½ÉÀüµµ»ó ½É½Ç ±â¿Ü ¼öÃàÀÌ bigeminy·Î °üÂûµÇ¾ú´Ù. ȯÀÚ´Â °íÇ÷¾ÐÀ¸·Î Åõ¾à ÁßÀ̸ç Ç÷¾ÐÀº Àß Á¶Àý µÇ°í
ÃÖÇü¿À ±³¼ö
2015-10-16
|
|
|
|
[Case Review] ¹ßÀÛ¼º ½É¹æ¼¼µ¿ ȯÀÚ¿¡¼ Rytmonorm SR ó¹æ Áõ·Ê
Áõ·Ê60¼¼ ³²ÀÚ È¯ÀÚ°¡ ³»¿ø 1ÀÏÀüºÎÅÍ °©Àڱ⠽ÃÀÛµÈ µÎ±Ù°Å¸²À» ÁÖ¼Ò·Î ³»¿øÇÏ¿´´Ù.³»¿ø 1³â ÀüºÎÅÍ °£°£È÷ µÎ±Ù°Å¸²ÀÌ ÀÖ¾úÀ¸³ª °æ°ú °üÂûÇÏ´ø Áß ³»¿ø 1ÀÏÀü Àú³áºÎÅÍ °©Àڱ⠹߻ýÇÑ ¹Ýº¹µÇ´Â µÎ±Ù°Å¸²ÀÌ ÀÖ¾î ³»¿øÇÏ¿´´Ù. °ú°Å·Â»ó ƯÀÌ ÁúȯÀº ¾ø¾ú°í, »ç
È«½ÂÇ¥ ±³¼ö
2015-10-16
|
|
|
|
[Case Review] ½É¹æ¼¼µ¿ ȯÀÚ¿¡¼ ¸®Æ®¸ð³ðSR ó¹æ Áõ·Ê
Áõ·Ê60¼¼ ³²ÀÚ È¯ÀÚ°¡ ¹ßÀÛÀûÀ¸·Î ¹ß»ýÇÏ´Â ½É°èÇ×Áø ¹× ¿îµ¿½Ã È£Èí°ï¶õÀÌ ÀÖ¾î ½ÉÀå³»°ú ¿Ü·¡¸¦ ¹æ¹®ÇÏ¿´´Ù. ȯÀÚ´Â 6°³¿ù ÀüºÎÅÍ °íÇ÷¾Ð Á¶ÀýÀ» À§ÇØ Ä®½·±æÇ×Á¦ (amlodipine 5mg)¸¦ º¹¿ëÇÏ°í ÀÖ¾úÀ¸¸ç ³»¿ø½Ã Ç÷¾ÐÀº 130/80mmHg, ¸Æ¹ÚÀº
ȲÀǼ® ±³¼ö
2015-10-16
|
|
|
|
|
[VOD lecture] ´ë¿õÁ¦¾à, ¡®Á÷Àå¹è´Þ ÄܼƮ¡¯ ÁøÇà
¢ß´ë¿õÁ¦¾à(´ëÇ¥ ÀÌÁ¾¿í)Àº Áö³ 30ÀÏ °³²±¸ »ï¼ºµ¿ ´ë¿õÁ¦¾à º£¾îȦ¿¡¼ Æò¼Ò ¾÷¹«¿¡ ¸ôÀÔÇÑ ´ë¿õÁ¦¾àÀÇ ÀÓÁ÷¿øÀÌ Èú¸µÇÏ°í ÇູÇÏ°Ô ÀÏÇÒ ¼ö ÀÖµµ·Ï ¡®Á÷Àå¹è´Þ ÄܼƮ¡¯¸¦ ÁøÇàÇß´Ù
¾È¼ºÁ¾ ±âÀÚ
2015-10-02
|
|
|
|
|
|
|
[ÇмúÇà»ç] Lipid Management for diabetic patients
¿ì¸®³ª¶ó´Â ´ç´¢º´ ȯÀÚÀÇ 79.6%°¡ ÀÌ»óÁöÁúÇ÷ÁõÀ» µ¿¹ÝÇÏ°í ÀÖ´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ³ôÀº À¯º´·ü¿¡µµ ºÒ±¸ÇÏ°í ÀÌ»óÁöÁúÇ÷ÁõÀÇ Ä¡·áÀ²Àº 24%, Ä¡·á¿¡ µû¸¥ Á¶Àý·üÀº 18%¿¡µµ ¹ÌÄ¡Áö ¸øÇÏ´Â ½ÇÁ¤ÀÌ´Ù. ƯÈ÷ ´ç´¢º´¼º ÀÌ»óÁöÁúÇ÷ÁõÀº sdLDL(small de
¸ÞµðÄ®·³
2015-07-02
|
|
|
|
|
[ÇмúÇà»ç] The Role of Glycosaminoglycans in Vascular Disease
GCX(glycocalyx)´Â ÁÖ·Î ³»ÇǼ¼Æ÷¸·ÀÇ Ç¥ÇÇÃþÀÇ ±¸Á¶¹°À» ¸»ÇÏ´Â °ÍÀ¸·Î, À̸§¿¡¼ ¾Ë ¼ö ÀÖµíÀÌ ¸·°áÇÕ¼º proteoglycans¿¡ ¿¬°áµÈ GAG(glycosaminoglycan)À¸·Î ÀÌ·ç¾îÁ³´Ù. GAG Á¾·ù¿¡´Â HS(heparan sulfa
¸ÞµðÄ®·³
2015-07-02
|
|
|
|
|
|
|
[ÇмúÇà»ç] An Effective Management for Hypertension
FOCUS Study´Â ±¹³»¿¡¼ ÁøÇàÇÑ ¿¬±¸·Î, °íÇ÷¾Ð ȯÀÚ 370¸í´ë»óÀ¸·Î, nifedipine°ú valsartan Àú¿ë·® º´¿ë¿ä¹ý°ú µÎ ¾àÁ¦ °¢°¢ÀÇ °í¿ë·® ´ÜÀÏ¿ä¹ýÀÌ Á᫐ Ç÷¿ªÇп¡ ¹ÌÄ¡´Â ¿µÇâÀ» ºñ±³ÇÑ ÀÓ»óÀÌ´Ù. °íÇ÷¾Ð ÃøÁ¤ÀÇ ¿©·¯ ¹æ¹ý Áß Áß½ÉÇ÷
¾È¼ºÁ¾ ±âÀÚ
2015-05-28
|
|
|
|
|
|
|
[ÇмúÇà»ç] Recent concept of treatment for lumbar degenerative diseases
Á¤Çü¿Ü°ú¿¡¼´Â ´ë°³ X-ray ¼Ò°ßÀ» ±Ù°Å·Î ¼ö¼ú °á°ú¸¦ Æò°¡ÇÏÁö¸¸, ÀÌ·¯ÇÑ ¿µ»ó ¼Ò°ß°ú ÀÓ»ó °á°ú ¹× Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¸¸Á·µµ°¡ ¼·Î ÀÏÄ¡ÇÏÁö ¾ÊÀº °æ¿ìµµ ²Ï ¸¹´Ù. ÀÌ °æ¿ì ¼ö¼úÀ» Çß´ø ¿Ü°úÀǵéÀº ´ë°³ ȯÀÚ°¡ È£¼ÒÇÏ´Â ³»¿ëº¸´Ù ¿µ»ó °Ë»ç °á°ú¿¡ ÃÊ
¸ÞµðÄ®·³
2015-02-16
|
|
|
|
|
|
|
|
|
[ÇмúÇà»ç] The risk management of CVD with low dose Aspirin
¿¾³¯ºÎÅÍ ¹öµå³ª¹«´Â ÅëÁõÀÌ ÀÖÀ» ¶§ ¾àÀ¸·Î »ç¿ëµÇ¾úÀ¸¸ç, 1800³â´ë Á߹ݿ¡ À̸£·¯¼´Â ÀÌ ¹öµå³ª¹«¿¡¼ ÃßÃâÇÑ »ì¸®½Ç»ê(salicylic acid)¿¡ ÁøÅëÈ¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³´Ù. ÀÌÈÄ 1899³â ¹ÙÀÌ¿¤¿¡¼ ÀÏÇÏ´ø Felix HoffmanÀÌ ¹öµå³ª
¸ÞµðÄ®·³
2015-01-30
|
|
|
|
|
[ÇмúÇà»ç] Recent Advances in Platelet Aggregation Inhibitors
Ç÷¼ÒÆÇ È°¼ºÈ °úÁ¤Àº ¿©·¯ °æ·Î ¹× ÀÎÀÚ°¡ ÀÛ¿ëÇϱ⠶§¹®¿¡ ¸Å¿ì º¹ÀâÇÏÁö¸¸, ´Ü¼øÈ÷ µµ½ÄÈÇϸé Ç÷°üº®ÀÌ ¼Õ»óÀ» ÀÔÀ¸¸é, È°¼ºÈµÈ Ç÷¼ÒÆÇÀÌ µ¿¿ø ¹× ºÎÂøµÇ¸é¼, ÁöÇ÷µÇ´Â °ÍÀ¸·Î Á¤¸®ÇÒ ¼ö ÀÖ´Ù. Ç÷¼ÒÆÇ È°¼ºÈ´Â Å©°Ô ADP, Æ®·Òºó(thrombin),
¸ÞµðÄ®·³
2015-01-29
|
|
|
|
[Topic] °æÃß ¼Õ»óÀÇ Ãʱâ Ä¡·á
°æÃßÀÇ °ñÀý ¹× Å»±¸´Â ½ÉÇÑ ºÒ±¸ ¹× Á×À½±îÁö ÃÊ·¡ÇÒ ¼ö ÀÖ´Â ¼Õ»óÀ¸·Î¼, Àå±â°£ÀÇ ÀÔ¿ø ¹× ¿ÏÀü ºÒ±¸·Î ÀÎÇÑ °³ÀÎ, °¡Á· ¹×»çȸ¿¡ ¹ÌÄ¡´Â ¿µÇâÀÌ Å©±â ¶§¹®¿¡ ±× Ä¡·á ¹× ÀçÈ°ÀÇ Á߿伺ÀÌ °Á¶µÇ¾î ¿Ô´Ù. ¾ÈÀüº§Æ®ÀÇ Âø¿ëÀÌ ´Ã¾î³²¿¡ µû¶ó Èä¿äÃßÀÇ °ñÀýÀº
°Ã¢³²±³¼ö
2015-01-27
|
|
|
|
[Topic] °æÃß ¼Õ»óÀÇ ¹æ»ç¼±ÇÐÀû Áø´Ü
¹Ì±¹ ÀÀ±Þ ¹æ»ç¼± °Ë»ç ÀÌ¿ë ¿¬±¸(National Emergency X-radiography Utilization Study, NEXUS)¿¡¼´Â ´ÙÀ½°ú °°Àº 5°¡Áö»çÇ×ÀÌ ÀÖ´Â °æ¿ì´Â °æÃß ¼Õ»óÀÇ °¡´É¼ºÀÌ ÀûÀ¸¹Ç·Î, ¹æ»ç¼± °Ë»ç¸¦ ÇÏÁö ¾Ê¾Æµµ µÈ´Ù°í ÇÏ
±èÈ£Áß±³¼ö
2015-01-27
|
|
|
|
|
[ÇмúÇà»ç] Lipid Management for diabetic patients
Áö³ 2013³â 11¿ù ¹ßÇ¥µÈ ACC/AHA °¡À̵å¶óÀο¡¼´Â ´ÙÀ½ÀÇ 4°³ ȯÀÚ±º¿¡°Ô statin Ä¡·á¸¦ ±ÇÇÏ°í ÀÖ´Ù. ù°, Class II-IV¿¡ ÇØ´çÇÏ´Â ½ÉºÎÀüÀ» µ¿¹ÝÇÏÁö ¾ÊÀ¸¸ç Åõ¼®Ä¡·á°¡ ÇÊ¿äÄ¡ ¾ÊÀº Á׻󵿸ưæȼº½ÉÇ÷°üÁúȯ(atherosclero
¸ÞµðÄ®·³
2015-01-07
|
|
|
|
|
[ÇмúÇà»ç] Recent Advances in Platelet Aggregation Inhibitors
Ç÷¼ÒÆÇ Çü¼º ¹× ÀÀ°í °úÁ¤¿¡¼´Â Ç÷¼ÒÆÇ È°¼ºÈ¿Í ÇÔ²² Æ®·Òºó(thrombin)ÀÇ ÀÛ¿ëÀ¸·Î ÁöÇ÷ÀÌ ÀÌ·ç¾îÁö¸é¼ Ç÷±«(clot)°¡ Çü¼ºµÇ±â ¶§¹®¿¡ ³úÁ¹ÁßÀ» ºñ·ÔÇÑ ½É³úÇ÷°üÁúȯÀÇ Ä¡·á¿Í ¿¹¹æ¿¡´Â ÁÖ·Î ÀÌ ´Ü°è¸¦ Â÷´ÜÇÏ´Â ¾àÁ¦µéÀÌ ÁÖ·Î »ç¿ëµÈ´Ù. ƯÈ÷ P2Y
¸ÞµðÄ®·³
2015-01-07
|
|
|
|
|
[ÇмúÇà»ç] HTN Management: FOCUS study
Ç÷¾Ð ÃøÁ¤ÀÇ ±â¿ø ¹× Áß½ÉÇ÷¾ÐÀÇ Á߿伺¡ß Ç÷¾ÐÀÇ ÀÓ»óÀû ÀÇ¹Ì : ÀϹÝÀûÀ¸·Î »ó¿Ï¿¡¼ ÃøÁ¤ÇÑ Ç÷¾ÐÀ» ±Ù°Å·Î °íÇ÷¾Ð Ä¡·á¸¦ ÇÏ¸é µÈ´Ù°í »ý°¢ÇÏÁö¸¸, ´Ü¼øÈ÷ »ó¿Ï¿¡¼ ÃøÁ¤ÇÑ Ç÷¾Ð¸¸ ±âÁØÀ¸·Î ÇÏ´Â °Íº¸´Ù Áß½ÉÇ÷¾Ð, pressure wave form¿¡¼ ÆÄ»ýÇÏ
¸ÞµðÄ®·³
2015-01-06
|
|
|